Pro-Dex (Pro-Dex) ROCE % : 7.34% (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Pro-Dex ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pro-Dex's annualized ROCE % for the quarter that ended in Dec. 2023 was 7.34%.

Pro-Dex ROCE % Historical Data

The historical data trend for Pro-Dex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pro-Dex ROCE % Chart

Pro-Dex Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

29.25

34.52

26.58

17.16

24.94

Pro-Dex Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															43.03	20.88	54.05	-6.67	7.34

Pro-Dex ROCE % Calculation

Pro-Dex's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	9.961	/	( ( (49.089 - 11.354)	+	(51.823 - 9.676) )	/ 2 )
	=	9.961	/	( (37.735	+	42.147)	/ 2 )
	=	9.961	/	39.941
	=	24.94 %

Pro-Dex's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	3.036	/	( ( (49.585 - 8.281)	+	(51.427 - 9.99) )	/ 2 )
	=	3.036	/	( ( 41.304	+	41.437 )	/ 2 )
	=	3.036	/	41.3705
	=	7.34 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Pro-Dex (NAS:PDEX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pro-Dex ROCE % Related Terms

Thank you for viewing the detailed overview of Pro-Dex's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pro-Dex (Pro-Dex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pro-Dex Inc (NAS:PDEX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PDXN:Germany

Address

2361 McGaw Avenue, Irvine, CA, USA, 92614

Website

https://www.pro-dex.com

Pro-Dex Inc is engaged in designing, developing, and manufacturing powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. In addition, the company provides engineering consulting and placement services, as well as quality and regulatory consulting services. Most of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.

Executives

Angelita Rebamontan Domingo	director	1431 MADISON ST., TUSTIN CA 92782
Van Kirk Richard Lee Jr	director, officer: Chief Executive Officer	34 DEER CREEK, IRVINE CA 92604
Philp Katrina Marie Kramer	director	5501 NANTUCKET PL, MINNETONKA MN 55345
Farrell William James Iii	director	20200 COTTAGEWOOD RD, DEEPHAVEN MN 55331
Peter O. Haeg	10 percent owner	12701 WHITEWATER DR, SUITE 190, MINNETONKA MN 55343
Alisha Charlton	officer: Chief Financial Officer	25541 COMMERCENTRE DRIVE, LAKE FOREST CA 92630
Nicholas John Swenson	10 percent owner	5000 WEST 36TH STREET, SUITE 130, MINNEAPOLIS MN 55416
Raymond E Cabillot	director	3033 EXCELSIOR BLVD., STE 560, MINNEAPOLIS MN 55416
David Hovda	director
Farnam Street Partners Lp /mn	10 percent owner	3033 EXCELSIOR BOULEVARD, MINNEAPOLIS, MINNEAPOLIS MN 55416
Ao Partners I, Lp	10 percent owner	5000 WEST 36TH STREET, SUITE 130, MINNEAPOLIS MN 55416
David Holder	director	1052 CHARWOOD LANE, SANTA ANA CA 92705
William L Healey	director	101 BULLITT LANE, STE 450, LOUISVILLE KY 40222
Michael J Berthelot	director	P O BOX 7277, RANCHO SANTA FE CA 92067
George J Isaac	director	36 WHISPER DRIVE, WORCESTER MA 01609